RARA and acute promyelocytic leukemia: Remarkably, only a few arsenic-modulated His10-SUMO2 targets identified in the previous Pml+/+ APL cohorts also varied upon arsenic treatment in Pml-deficient APL mice, PML/RARA being the top enhanced one (Supplementary Data 4).